Lunai Bioworks is announcing a binding, $20 million strategic transaction acquiring drug delivery technology and assets from the Clemann Group. Lunai describes itself as an AI-driven life sciences company; Clemann Group supports activities from discovery to clinical and marketization activities.

Details on Acquisition from Clemann

The acquisition consists of blood-brain barrier (BBB) delivery technology and central nervous system (CNS) Alzheimer’s disease drug assets. It is a Series B Convertible Preferred transaction at a fixed conversion price of $1.50 per share. Consequently, this is subject to a 19.9% beneficial ownership limitation. There are no variable pricing or reset provisions.

Lunai says the acquisition gives the company a delivery platform addressing one of CNS drug development’s most crucial bottlenecks. Namely, the issue is the effective transportation of therapeutics into the brain. Traditional drugs struggle to penetrate the brain effectively, calling safety and efficacy into question.

Conversely, this platform’s underlying chemistry lets compounds cross the BBB, stay inactive in the body, then activate inside the brain.

More specifically, according to Lunai, the platform’s mechanism of action targets pathways central to acetylcholinesterase modulation in the brain. These pathways are broadly implicated in neurological disease.

Lunai Bioworks Adds to CNS Pipeline

In making this acquisition, Lunai says it is strengthening its CNS Alzheimer’s pipeline, pairing biological target identification with proven delivery. The company hopes to leverage the platform to develop next-generation treatments for a wider range of CNS disorders.

“This is a step-change in our capabilities,” said Lunai Bioworks CEO David Weinstein. “[We’re] combining the ability to identify the right biology with a validated mechanism to deliver therapies directly into the brain. This has profound implications for how we treat Alzheimer’s and other complex CNS diseases that have historically been unreachable.”